Clinical Trial Update: Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating canakinumab for cytokine release syndrome in COVID-19–related pneumonia completed; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytokine Release Syndrome in Patients with Covid-19-induced Pneumonia

Drugs mentioned

• Canakinumab (canakinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Cytokine Release Syndrome (CRS) in Patients With COVID-19-induced Pneumonia | Phase 3 | Status: COMPLETED | Results posted: 2021-08-16